Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have defined a path forward for roluperidone’s clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback